ReviewMetabolites2022
Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome.
Review in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Prevalence and predictors of metabolic syndrome among psychiatric patients receiving antipsychotic treatment in Africa: a systematic review and meta-analysis.BMC psychiatry · 2025Pooled it
- Prevalence of metabolic syndrome and its components according to altitude levels: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Comparison of the effects of antipsychotic and combined with non-invasive brain stimulation on blood lipids in patients with schizophrenia.BMC psychiatry · 2026Article
- Cognitive functions in schizophrenia: the interplay between blood viscosity, serum osmolarity, and symptom severity.BMC psychiatry · 2025Article
- Gut microbiome and metabolism alterations in schizophrenia with metabolic syndrome severity.BMC psychiatry · 2024Article
- Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model.CNS neuroscience & therapeutics · 2024Article
- Validity of handgrip strength for assessing cognition and psychotic symptoms in hospitalized patients with stable schizophrenia.PloS one · 2024Article
- Body Weight Variability and Risk of Suicide Mortality: A Nationwide Population-Based Study.Depression and anxiety · 2024Article
- Valproate-Induced Metabolic Syndrome.Biomedicines · 2023Review
- Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study andFrontiers in medicine · 2023Article
- Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). Antipsychotic (AP)-induced MetS (AIMetS) is the most common adverse drug reaction (ADR) of psychiatric pharmacotherapy. Herein, we review the results of studies of blood (serum and plasma) and urinary biomarkers as predictors of AIMetS in patients with schizophrenia (Sch). We reviewed 1440 studies examining 38 blood and 19 urinary metabolic biomarkers, including urinary indicators involved in the development of AIMetS. Among the results, only positive associations were revealed. However, at present, it should be recognized that there is no consensus on the role of any particular urinary biomarker of AIMetS. Evaluation of urinary biomarkers of the development of MetS and AIMetS, as one of the most common concomitant pathological conditions in the treatment of patients with psychiatric disorders, may provide a key to the development of strategies for personalized prevention and treatment of the condition, which is considered a complication of AP therapy for Sch in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.